{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:31:11Z","timestamp":1790008271300,"version":"4.0.1"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/cco.0b013e32834bcc2a","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:56:09Z","timestamp":1317758169000},"page":"672-680","source":"Crossref","is-referenced-by-count":46,"title":["Therapy-related myeloid neoplasms"],"prefix":"10.1097","volume":"23","author":[{"given":"Giuseppe","family":"Leone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Fianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria T.","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20210128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R3-19-20210128","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","article-title":"Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDSMPN but has no independent prognostic relevance: a comparison of 408 cases classified as AML not otherwise specified (AML-NOS) or AML with myelodysplasia-related changes (AML-MRC).","volume":"116","author":"Miesner","year":"2010","journal-title":"Blood"},{"key":"R4-19-20210128","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML.","volume":"117","author":"Kayser","year":"2011","journal-title":"Blood"},{"key":"R5-19-20210128","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2007-10-115600","article-title":"Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.","volume":"112","author":"Hasan","year":"2008","journal-title":"Blood"},{"key":"R6-19-20210128","doi-asserted-by":"crossref","first-page":"e16623","DOI":"10.1371\/journal.pone.0016623","article-title":"Chromosomal minimal critical regions in therapy-related leukemia appear different from those of de novo leukemia by high-resolution aCGH.","volume":"6","author":"Itzhar","year":"2011","journal-title":"PLoS One"},{"key":"R7-19-20210128","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"R8-19-20210128","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","article-title":"Genome-wide association study identifies novel breast cancer susceptibility loci.","volume":"447","author":"Easton","year":"2007","journal-title":"Nature"},{"key":"R9-19-20210128","doi-asserted-by":"crossref","first-page":"5575","DOI":"10.1182\/blood-2008-10-183244","article-title":"Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.","volume":"113","author":"Knight","year":"2009","journal-title":"Blood"},{"key":"R10-19-20210128","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.0b013e318211c3c8","article-title":"Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.","volume":"76","author":"Hasan","year":"2011","journal-title":"Neurology"},{"key":"R11-19-20210128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3816\/CLML.2011.n.016","article-title":"Associated malignancies in patients with Waldenstroms macroglobulinemia and their kin.","volume":"11","author":"Hanzis","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R12-19-20210128","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.bcmd.2010.05.008","article-title":"Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.","volume":"45","author":"Greco","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"R13-19-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10549-009-0597-5","article-title":"Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).","volume":"119","author":"Slovak","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R14-19-20210128","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.2008.17.1033","article-title":"Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma.","volume":"27","author":"Chakraborty","year":"2009","journal-title":"J Clin Oncol"},{"key":"R15-19-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"R16-19-20210128","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"key":"R17-19-20210128","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1182\/blood-2008-11-187880","article-title":"Methotrexate6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.","volume":"113","author":"Schmiegelow","year":"2009","journal-title":"Blood"},{"key":"R18-19-20210128","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood-2008-12-193250","article-title":"Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols.","volume":"114","author":"Stanulla","year":"2009","journal-title":"Blood"},{"key":"R19-19-20210128","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pbc.23083","article-title":"on behalf of EORTC Children Leukaemia Group (CLG)Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: low incidence of CNS tumours.","volume":"15","author":"Renard","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R20-19-20210128","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"key":"R21-19-20210128","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ejca.2011.03.022","article-title":"The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.","volume":"47","author":"Vrooman","year":"2011","journal-title":"Eur J Cancer"},{"key":"R22-19-20210128","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2010.29.2268","article-title":"Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy.","volume":"28","author":"Montesinos","year":"2010","journal-title":"J Clin Oncol"},{"key":"R23-19-20210128","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence.","volume":"92","author":"Leone","year":"2007","journal-title":"Haematologica"},{"key":"R24-19-20210128","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkins lymphoma: 10 years of follow-up of the GHSG HD9 study.","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"key":"R25-19-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/annonc\/mdq408","article-title":"Impact of first- and second-line treatment for Hodgkins lymphoma on the incidence of AMLMDS and NHL-experience of the German Hodgkins Lymphoma Study Group analyzed by a parametric model of carcinogenesis.","volume":"22","author":"Scholz","year":"2011","journal-title":"Ann Oncol"},{"key":"R26-19-20210128","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1200\/JCO.2010.28.9777","article-title":"Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.","volume":"29","author":"Tarella","year":"2011","journal-title":"J Clin Oncol"},{"key":"R27-19-20210128","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1200\/JCO.2007.15.1530","article-title":"Increased incidence of transformation and myelodysplasiaacute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs.","volume":"27","author":"Leleu","year":"2009","journal-title":"J Clin Oncol"},{"key":"R28-19-20210128","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2010.218","article-title":"Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.","volume":"24","author":"Carney","year":"2010","journal-title":"Leukemia"},{"key":"R29-19-20210128","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"R30-19-20210128","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.","volume":"29","author":"Woyach","year":"2011","journal-title":"J Clin Oncol"},{"key":"R31-19-20210128","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1002\/cncr.25525","article-title":"Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.","volume":"116","author":"Gruschkus","year":"2010","journal-title":"Cancer"},{"key":"R32-19-20210128","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/leu.2009.179","article-title":"The use of novel agents in the treatment of relapsed and refractory multiple myeloma.","volume":"23","author":"Laubach","year":"2009","journal-title":"Leukemia"},{"key":"R35-19-20210128","first-page":"77","article-title":"Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer.","volume":"28","author":"Burnell","year":"2010","journal-title":"Clin Oncol"},{"key":"R36-19-20210128","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-009-0376-3","article-title":"Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study.","volume":"118","author":"Martin","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"R37-19-20210128","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735.","volume":"27","author":"Jones","year":"2009","journal-title":"J Clin Oncol"},{"key":"R38-19-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/CEJ.0b013e32832abd76","article-title":"Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study.","volume":"18","author":"Cluze","year":"2009","journal-title":"Eur J Cancer Prev"},{"key":"R39-19-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdn530","article-title":"Acute myeloid leukemia after breast cancer: a population-based comparison with hematological malignancies and other cancers.","volume":"20","author":"Beadle","year":"2009","journal-title":"Ann Oncol"},{"key":"R40-19-20210128","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R41-19-20210128","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2009.24.7643","article-title":"Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.","volume":"28","author":"Moebus","year":"2010","journal-title":"J Clin Oncol"},{"key":"R42-19-20210128","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr2860","article-title":"Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy.","volume":"13","author":"Zhang","year":"2011","journal-title":"Breast Cancer Res"},{"key":"R44-19-20210128","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.annepidem.2008.01.003","article-title":"Risk of leukemia among survivors of testicular cancer: a population-based study of 42,722 patients.","volume":"18","author":"Howard","year":"2008","journal-title":"Ann Epidemiol"},{"key":"R45-19-20210128","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/thy.2008.0392","article-title":"Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis.","volume":"19","author":"Sawka","year":"2009","journal-title":"Thyroid"},{"key":"R46-19-20210128","first-page":"8","article-title":"Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy.","volume":"1-","author":"Iyer","year":"2011","journal-title":"Cancer"},{"key":"R48-19-20210128","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1200\/JCO.2008.21.1920","article-title":"Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort.","volume":"27","author":"Meadows","year":"2009","journal-title":"J Clin Oncol"},{"key":"R49-19-20210128","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ijc.25067","article-title":"Secondary malignant neoplasms after Wilms tumor: an international collaborative study.","volume":"127","author":"Breslow","year":"2010","journal-title":"Int J Cancer"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32834bcc2a","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:27:27Z","timestamp":1786048047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201111000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32834bcc2a","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}